This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D80.6 | Synonyms: Antibody deficiency with near-normal immunoglobulins, Specific antibody deficiency (SAD)
In the 1970s–1980s, as patients whose total serum immunoglobulin levels were normal but who failed to respond to vaccination were found in clinical practice, interest in abnormalities of antibody function increased. Traditionally, immunodeficiency was defined by a decrease in total immunoglobulin, but it was recognized that functional antibody responses to specific antigens may be lacking even when immunoglobulin levels are normal or elevated.
When Sorensen and Polmar (1984) and Ambrosino et al. (1988) described a group of patients who failed to respond to pneumococcal polysaccharide vaccine despite normal serum immunoglobulins, the concept of "Specific Antibody Deficiency (SAD)" was established. This concept shows that functional responsiveness, not the total amount of antibody, is the core of immune defense.
The European Society for Immunodeficiencies (ESID) and the Immune Deficiency Foundation (IDF) in the US define ICD-10 D80.6 as a category that includes IgG subclass deficiency, specific antibody deficiency, and some antibody deficiencies with hyperimmunoglobulinemia.
In Korea, independent epidemiological data on specific antibody deficiency are lacking, and it is diagnosed sporadically, mainly in the course of evaluating recurrent respiratory infections or immunodeficiency. Diagnoses have been increasing since the 2010s, when pneumococcal polysaccharide vaccine response testing began to be used clinically.
Specific antibody deficiency is caused by a defect in the B-cell response to T-cell-independent polysaccharide antigens or a defect in the response to T-cell-dependent protein-conjugated antigens. In particular, a selective defect in the IgG response to pneumococcal capsular polysaccharide antigens is characteristic.
The IgG2 subclass is mainly involved in antibody responses to polysaccharide antigens, and IgG2 deficiency is closely associated with specific antibody deficiency. IgG1 and IgG3 deficiencies are also associated with reduced responses to protein antigens.
This refers to cases in which total IgG or IgM is elevated but specific antibody production is deficient, caused by overproduction of nonfunctional antibodies. Differentiation from secondary causes such as HIV infection and EBV infection is necessary.
Post-splenectomy status, functional asplenia such as in sickle cell anemia, immunosuppression after organ transplantation, and steroid therapy can secondarily cause deficient antibody function.
The genes encoding IgG subclasses are in the immunoglobulin heavy chain constant region gene cluster (IGHG1–IGHG4) located at 14q32.33. Some IgG subclass deficiencies are reported to be due to deletions of these genes. Deletion of the IGHG2 gene can cause IgG2 deficiency.
Most specific antibody deficiency has a polygenic predisposition, with polymorphisms in immune regulatory genes contributing in combination rather than a single-gene defect. TACI (TNFRSF13B) and BAFF-R variants are found in some patients.
Most cases are sporadic, but familial clustering is rarely reported. Related antibody immunodeficiencies such as selective IgA deficiency and CVID are sometimes present in siblings or parents.
Specific antibody deficiency (SAD) is estimated to be one of the most commonly found primary immunodeficiencies in the immunodeficiency evaluation of children with recurrent infections. Some studies report that SAD is found in 10–20% of children with recurrent otitis media or sinusitis.
It is most often diagnosed in children, especially at 2–5 years of age. Because responses to polysaccharide antigens are immature in young children, differentiation from physiological "immaturity of the antibody response" is important (in general, polysaccharide vaccine responses are not mature at 2 years of age or younger).
No major difference between males and females is reported. Some studies have reported a slight male predominance of IgG2 deficiency-related SAD in children.
In Korea, SAD is increasingly recognized in the field of pediatric immunology and allergy, which evaluates children with recurrent respiratory infections. Diagnoses have been increasing since the 2010s, when pneumococcal polysaccharide vaccine response testing began to be used clinically.
Polysaccharide antigens stimulate B cells in a T-cell-independent manner, mainly inducing IgM and IgG2 antibodies. Splenic marginal zone B cells play a key role in this response. Immaturity, deficiency, or dysfunction of splenic marginal zone B cells has been proposed as a major pathogenesis of specific antibody deficiency.
IgG2 is the predominant isotype in antibody responses to polysaccharides. In patients with IgG2 deficiency, opsonization responses to encapsulated bacteria such as pneumococcus and Haemophilus influenzae are reduced, and the risk of invasive infection increases.
This refers to cases in which total IgG is elevated but specific antibody function is deficient, with nonspecific or autoreactive antibodies making up the majority while pathogen-specific antibodies are not produced. Chronic immune stimulation (chronic infection, autoimmune disease) can cause this condition.
The most common symptoms are recurrent otitis media, sinusitis, pneumonia, and bronchitis. In children, 4 or more episodes of otitis media per year, 2 or more episodes of pneumonia, or chronic sinusitis (lasting 3 months or longer) are characteristic.
Bacteremia, meningitis, and pneumonia caused by pneumococcus and Haemophilus influenzae occur rarely. Reduced opsonization responses to encapsulated bacteria increase the risk of invasive infection.
In children, as the immune system matures with age, specific antibody responses improve and symptoms often improve. In some, symptoms persist or worsen into adulthood, and in these cases there is also a possibility of transition to CVID.
The severity of symptoms is highly variable, showing a broad spectrum from mild recurrent upper respiratory infections to severe invasive infections.
Chronic otorrhea (ear discharge), nasal polyps, and sinus tenderness due to recurrent infections may be observed. In some patients who develop bronchiectasis, wheezing and abnormal breath sounds may be heard on auscultation.
Serum IgG, IgA, and IgM are within the normal range, or in some patients hyperimmunoglobulinemia (elevated total IgG or IgM) is observed. IgG subclass testing may reveal decreased IgG2 or IgG4.
If, 4–6 weeks after pneumococcal polysaccharide vaccine (PPSV23) vaccination, the serum antibody response increases less than 2-fold or fails to reach protective titers (>1.3 μg/mL per serotype), SAD is strongly suggested. A normal response is defined as a 4-fold or greater antibody increase or achievement of protective titers for 70% or more of the vaccine serotypes.
In patients with recurrent infections whose quantitative serum immunoglobulin (IgG, IgA, IgM) tests are normal, IgG subclass (IgG1–IgG4) testing is performed. If IgG subclasses are also normal or borderline, SAD is evaluated by specific antibody response testing before and after pneumococcal polysaccharide vaccination.
In children under 2 years of age, responses to polysaccharide antigens are physiologically insufficient, so caution is needed in diagnosing SAD. At this age, evaluation by the response to protein-conjugated pneumococcal vaccine (PCV) is more appropriate.
Because it may be difficult to draw a conclusion from a single test, retesting after 3–6 months is used to assess the persistence of the response and changes in immune function.
① Serum IgG, IgA, and IgM normal or elevated ② Insufficient specific antibody response after pneumococcal polysaccharide vaccine (PPSV23) vaccination (failure to reach protective titers or less than 4-fold increase in 50–70% or more of the target serotypes) ③ Exclusion of secondary causes
IgG subclass deficiency is diagnosed when quantitative serum IgG subclass testing (IgG1–IgG4) confirms levels below the age-specific lower limit of normal on 2 or more occasions. IgG2 deficiency is the most clinically significant.
Differential diagnoses include ① CVID (low IgG + low IgA + poor antibody response) ② selective IgA deficiency ③ XLA ④ secondary antibody deficiency (immunosuppressants, protein loss, splenic dysfunction) ⑤ physiological antibody immaturity (children).
Appropriate vaccination with pneumococcal conjugate vaccine (PCV13/PCV15) and polysaccharide vaccine (PPSV23), as well as Hib vaccine, meningococcal vaccine, and influenza vaccine, is recommended.
When recurrent infections are severe, low-dose prophylactic antibiotics (amoxicillin, azithromycin) are given for 3–6 months and their effect is evaluated.
Indications for IVIG or SCIG therapy in SAD and IgG subclass deficiency are applied strictly. IVIG is considered in severe recurrent infections, development of bronchiectasis, or failure of prophylactic antibiotics. Because many children improve with maturation, reassessment of when to stop treatment is necessary.
Regular follow-up of serum IgG subclasses, reassessment of immune function, and pulmonary function tests (monitoring for bronchiectasis) are recommended.
In many pediatric patients, specific antibody responses improve with increasing age and symptoms tend to improve spontaneously. Regular follow-up has reported cases in which immunoglobulin levels and antibody responses normalize after adolescence.
In some, the deficiency persists into adulthood, and rarely it progresses to CVID. When recurrent infections persist over a long period, bronchiectasis may develop, which can cause permanent damage to lung function.
With appropriate management, most patients can maintain a good quality of life. Diagnosing the condition and starting preventive treatment before bronchiectasis or chronic lung disease develops is key to improving the prognosis.
Early vaccination with protein-conjugated vaccines (PCV) against encapsulated bacteria can induce protective antibodies through T-cell-dependent responses. Influenza vaccine is given every year.
Prompt antibiotic treatment when infection occurs prevents progression to lower respiratory tract infection and bronchiectasis.
Patients are educated on early recognition of abnormal infection symptoms, ways to minimize exposure to infection-prone environments (daycare centers, group living facilities), and the importance of hand hygiene. Patients and caregivers are informed of the importance of regular follow-up testing of immune function.